~~<i id='EEFE426FDA'><strike id='EEFE426FDA'><tt id='EEFE426FDA'><pre id='EEFE426FDA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：explore 2025-08-19 15:00:48 - browse：28

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： FDA approves first blood sugar monitor without finger pricks

hotspot

knowledge

hotspot

focus

hotspot

ThousandsofIsraelismarchtoJerusaleminprotestofplansbyPrimeMinisterBenjaminNetanyahu'sgovernmenttoove

WSS

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Ransomware attacks on hospitals: Study outlines patient impact

Hospitals look to new technology to keep health care workers safe

A daunting task: navigating dual Medicare, Medicaid eligibility

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

focus

comprehensive

hotspot

Medicare details structure of new drug price negotiation program

U.K. considers world's first use of meningitis vaccine to address gonorrhea

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The response to Covid

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Severe heat forecast: Where scorching temperatures will persist over the next week

In age of alternative facts, a scholarly course on calling out crap

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA's Woodcock to retire early next year

knowledge

David Sabatini, ex

NYU radiologists take on the challenge of expensive MRI machines

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Morphosys mixed study results for blood cancer drug

In key trial, Verve's treatment lowers cholesterol levels in patients

CRISPR pioneers react to Casgevy, first gene

hotspot

hotspot

focus

hotspot